Summarized by Masters of Longevity from PR Newswire.
Phase 3b exploratory data report broader biomarker shifts when an IL-17A inhibitor is given with a GIP/GLP-1 receptor agonist in adults with psoriasis and obesity.
Key Takeaways
- Concomitant treatment produced more differentially expressed proteins by Week 36 than IL-17A inhibitor alone, 482 versus 140 proteins.
- Concomitant treatment produced more differentially expressed genes by Week 36 than IL-17A inhibitor alone, 467 versus 16 genes.
- A subset of neutrophil-associated markers partly mediated additional PASI improvement seen with the combined therapy versus monotherapy.
